Compare CRUS & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRUS | PTCT |
|---|---|---|
| Founded | 1984 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.1B |
| IPO Year | 1989 | 2013 |
| Metric | CRUS | PTCT |
|---|---|---|
| Price | $144.29 | $69.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 18 |
| Target Price | ★ $147.60 | $76.28 |
| AVG Volume (30 Days) | 814.5K | ★ 1.0M |
| Earning Date | 02-03-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.60 | N/A |
| EPS | 7.56 | ★ 8.94 |
| Revenue | ★ $1,973,312,000.00 | $1,779,150,000.00 |
| Revenue This Year | $1.37 | $132.16 |
| Revenue Next Year | $2.76 | N/A |
| P/E Ratio | $18.79 | ★ $7.91 |
| Revenue Growth | 7.04 | ★ 97.54 |
| 52 Week Low | $75.83 | $35.95 |
| 52 Week High | $146.88 | $87.50 |
| Indicator | CRUS | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 68.02 | 37.18 |
| Support Level | $139.26 | $69.75 |
| Resistance Level | $146.88 | $76.99 |
| Average True Range (ATR) | 6.77 | 2.60 |
| MACD | 0.73 | -0.44 |
| Stochastic Oscillator | 82.83 | 13.85 |
Cirrus Logic Inc is a provider of integrated circuits for audio and voice signal processing applications. The firm's products are organized into two streams: portable audio products, and HPMS Products. These products include aAmplifiers, codecs, smart codecs, analog-to-digital converters, digital-to-analog converters and standalone digital signal processors, Camera controllers, haptics and sensing solutions, and battery and power ICs. Roughly half of the firm's revenue is generated in China, with the rest coming from the United States, Europe, South Korea, and countries across the world.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.